https://www.selleckchem.com/products/ykl5-124.html
98). Worst grade toxicities like allergy (pooled RR 1.86; 95% CI 1.06-3.24) and neurotoxicity (pooled RR 5.59; 95% CI 1.43-21.84) were significantly higher among patients receiving paclitaxel combination therapy when compared to patients receiving PLD combination therapy. To summarize, PLD combination therapy is non-inferior to paclitaxel combination therapy in the management of ovarian cancer with respect to survival outcomes and worst grade toxicity profile. However, clinical recommendations cannot be made, as the evidence is not con
Like
Comment
Share
